Want to see VANI full AI Analyst Report?
VANI Stock Chart & Stats
$1.28
-$0.02(-1.59%)
At close: 4:00 PM EST
$1.28
-$0.02(-1.59%)
Day’s Range― - ―
52-Week Range$0.92 - $1.92
Previous CloseN/A
Volume36.09K
Average Volume (3M)216.92K
Market Cap
$108.66M
Enterprise Value$66.47M
Total Cash (Recent Filing)$19.75M
Total Debt (Recent Filing)$18.27M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 18, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding86,235,110
10 Day Avg. Volume237,036
30 Day Avg. Volume216,922
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-511.28
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$4.00Price Target Upside212.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (SLIM-1 Approval)HREC approval to start SLIM-1 materially advances Vivani from preclinical to clinical development in a key indication (obesity). This reduces near-term regulatory gating risk, enables generation of human safety and PK data needed for partnering/IND decisions and supports longer-term development and commercialization paths.
Proprietary Long‑acting Implant PlatformVivani’s nanoportal long‑acting implant approach targets chronic disease segments where sustained dosing is desirable. A differentiated delivery platform can create structural advantages—sticky product use, potential for repeatable indications, and higher commercial defensibility versus oral or injectable therapies over multi-year horizons.
Governance And Incentive AlignmentBoard elections and an updated omnibus incentive plan strengthen governance and align management pay with long‑term clinical and shareholder outcomes. Clear oversight and incentive design increase the odds of disciplined capital allocation, strategic execution and credible pursuit of clinical milestones or corporate restructuring.
Bears Say
No Revenue; Persistent Operating LossesThe absence of revenue and repeated multi‑million dollar operating losses indicate Vivani remains pre‑commercial and reliant on external funding. Over the medium term, a lack of commercialization traction increases financing frequency and dilution risk and leaves the business exposed to trial setbacks without offsetting cash inflows.
High Cash Burn And Limited RunwayReported cash of ~$28M versus ongoing operating cash outflows implies runway to mid‑2027 at current burn. Sustained negative free cash flow means the company will likely need to raise capital before key mid‑/late‑stage readouts, risking dilution, execution delays, or constrained development if markets or partnering windows tighten.
Rising Leverage And Weaker Balance SheetLeverage has increased meaningfully versus earlier periods, reducing financial flexibility. With negative returns on equity and elevated debt, adverse clinical or funding events would more quickly pressure liquidity or force expensive capital raises, increasing long‑term financing costs and potential shareholder dilution.
Vivani Medical News
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.92 and its highest was $1.92 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $108.66M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Aug 18, 2026 which is in 43 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.08.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 86,235,110 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (212.50% Upside)
$4.00 (212.50% Upside)
Insider Transactions
Bought Shares
Worth $6.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.12%
12-Months-Change
Fundamentals
Return on Equity
-264.04%
Trailing 12-Months
Asset Growth
19.47%
Trailing 12-Months
Company Description
Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.
VANI Stock 12 Month Forecast
Average Price Target
$4.00
▲(212.50% Upside)
Technical Analysis
Ownership Overview
48.71% Insiders
2.29% Mutual Funds
1.23% Other Institutional Investors
45.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---